Adagio Therapeutics (ADGI) : antibody will protect against omicron

• Co today provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, an investigational monoclonal antibody product candidate designed to provide broad neutralizing activity against SARS-CoV-2, to address the Omicron variant; co expects that ADG20 will retain activity against Omicron. Co is conducting in vitro studies to determine the neutralization activity of ADG20 against Omicron, and initial data is anticipated by the end of the year.